Exploring the Potential Drug Target or Biomarker Nature of RecQ4: A Protein-Like 4 in Chronic Pain Management

Target Name: RECQL4

NCBI ID: G9401

RECQL4

Exploring the Potential Drug Target or Biomarker Nature of RecQ4: A Protein-Like 4 in Chronic Pain Management

Abstract:
RecQ4 is a protein-like 4 that is expressed in various tissues and cell types, including the central nervous system (CNS). It has been associated with various neurological disorders, including chronic pain. The aim of this article is to review the current research on RecQ4 and its potential as a drug target or biomarker in the management of chronic pain.

Introduction:
Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with chronic pain reaching approximately $600 billion annually. Chronic pain can be caused by various conditions, including neurological disorders, metabolic diseases, and inflammatory diseases.

RecQ4 as a Potential Drug Target:
RecQ4 is a protein-like 4 that has been identified as a potential drug target in the management of chronic pain. Its unique structure and various functions make it an attractive target for small molecule inhibitors. Several studies have shown that RecQ4 can modulate pain perception and expression in various experimental models of chronic pain, including experimental models of neuroinflammation and neuro-immunomodulation.

RecQ4 as a Potential Biomarker:
In addition to its potential as a drug target, RecQ4 has also been identified as a potential biomarker for chronic pain. Several studies have shown that RecQ4 levels are decreased in individuals with chronic pain compared to individuals without chronic pain. Furthermore, RecQ4 has been shown to be associated with the expression of other genes involved in pain perception and chronic pain, including TrkA, TrkB, andCREB2. These findings suggest that RecQ4 may be a useful biomarker for the diagnosis and assessment of chronic pain.

RecQ4 as a Potential Negatively-Regulated gene:
RecQ4 has also been shown to be involved in the regulation of gene expression in chronic pain. Several studies have shown that RecQ4 can act as a negative regulator of TrkA, TrkB, andCREB2 genes, which are involved in pain perception and expression. This function of RecQ4 makes it a potential target for small molecule inhibitors that can modulate pain perception and expression.

Conclusion:
In conclusion, RecQ4 is a protein-like 4 that has been identified as a potential drug target and biomarker in the management of chronic pain. Its unique structure and various functions make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of RecQ4 in chronic pain management and to develop effective treatments.

Protein Name: RecQ Like Helicase 4

Functions: DNA-dependent ATPase. May modulate chromosome segregation

The "RECQL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RECQL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets